The estimated Net Worth of Bradford Crutchfield is at least $2.67 Million dollars as of 23 May 2022. Mr Crutchfield owns over 286 units of 10x Genomics stock worth over $2,148,938 and over the last 21 years he sold TXG stock worth over $167,684. In addition, he makes $350,000 as Chief Commercial Officer at 10x Genomics.
Mr has made over 32 trades of the 10x Genomics stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 286 units of TXG stock worth $13,945 on 23 May 2022.
The largest trade he's ever made was exercising 54,598 units of 10x Genomics stock on 21 December 2021 worth over $257,157. On average, Mr trades about 11,062 units every 18 days since 2004. As of 23 May 2022 he still owns at least 97,237 units of 10x Genomics stock.
You can see the complete history of Mr Crutchfield stock trades at the bottom of the page.
Bradford J. Crutchfield is the Chief Commercial Officer at 10x Genomics.
As the Chief Commercial Officer of 10x Genomics, the total compensation of Mr Crutchfield at 10x Genomics is $350,000. There are 9 executives at 10x Genomics getting paid more, with Serge Saxonov having the highest compensation of $2,362,960.
Mr Crutchfield is 58, he's been the Chief Commercial Officer of 10x Genomics since . There are 3 older and 13 younger executives at 10x Genomics. The oldest executive at 10x Genomics, Inc. is John Stuelpnagel, 62, who is the Independent Chairman of the Board.
Bradford's mailing address filed with the SEC is C/O 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON, CA, 94588.
Over the last 5 years, insiders at 10x Genomics have traded over $629,686,183 worth of 10x Genomics stock and bought 487,816 units worth $19,025,295 . The most active insiders traders include Bryan E Roberts, Capital Management I, Llc F..., and Benjamin J. Hindson. On average, 10x Genomics executives and independent directors trade stock every 8 days with the average trade being worth of $1,002,346. The most recent stock trade was executed by Serge Saxonov on 22 August 2024, trading 6,749 units of TXG stock currently worth $152,055.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
10x Genomics executives and other stock owners filed with the SEC include: